H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration

Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology

27-May-2014 - USA

H3 Biomedicine Inc. and Selvita announced that they have achieved the first research milestone in their strategic collaboration to develop breakthrough precision medicines for cancers. The companies have validated the importance and druggability of a kinase target in a specific genetic context and have generated multiple novel chemical series against this target. The companies expect the first candidate molecule originating from the collaboration to move to IND-enabling studies in 2015.

H3 Biomedicine will provide a milestone to Selvita in consideration of Selvita’s achievement of the first research goal in the project. The companies are not disclosing the amount.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances